Identification of a Klf4-dependent upstream repressor region mediating transcriptional regulation of the myocardin gene in human smooth muscle cells

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1829, Issue 11, 2013, Pages 1191-1201

  Turner, Elizebeth C ^a   Huang, Chien Ling ^a   Govindarajan, Kalaimathi ^a   Caplice, Noel M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Klf4; Myocardin; Platelet derived growth factor BB; Promoter; Smooth muscle cells; Transcription

Indexed keywords

KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MYOCARDIN; PLATELET DERIVED GROWTH FACTOR BB; SHORT HAIRPIN RNA;

ARTICLE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; GEL MOBILITY SHIFT ASSAY; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; REPRESSOR GENE; SITE DIRECTED MUTAGENESIS; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION;

ACTA2; CALPONIN; CARDIOVASCULAR DISEASE; CHIP; CHROMATIN IMMUNOPRECIPITATION; CNN1; CVD; FBS; FETAL BOVINE SERUM; IGG; IMMUNOGLOBULIN G; KLF; KLF4; KRÜPPLE-LIKE FACTOR; MYOCARDIN; PDGF-BB; PDGF-BB-RESPONSIVE REGION; PGL3E; PGL3ENHANCER; PLATELET-DERIVED GROWTH FACTOR BB; PLATELET-DERIVED GROWTH FACTOR-BB; PRL-THYMIDINE KINASE; PRL-TK; PROMOTER; PRR; RELATIVE LUCIFERASE UNIT; RLU; SDM; SEM; SERUM RESPONSE ELEMENT; SERUM RESPONSE FACTOR; SITE-DIRECTED MUTAGENESIS; SM; SM Α-ACTIN; SMC; SMOOTH MUSCLE; SMOOTH MUSCLE CELLS; SRE; SRF; STANDARD ERROR OF THE MEAN; TRANSCRIPTION; UPSTREAM REPRESSOR REGION; URR;

BASE SEQUENCE; CELLS, CULTURED; DNA PRIMERS; GENE EXPRESSION REGULATION; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MUSCLE, SMOOTH, VASCULAR; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-SIS; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 84885077954     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2013.09.002     Document Type: Article

References (57)

1. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 2004, 84:767-801.
2. Spin J.M., Maegdefessel L., Tsao P.S. Vascular smooth muscle cell phenotypic plasticity: focus on chromatin remodelling. Cardiovasc. Res. 2012, 95:147-155.
3. Alexander M.R., Owens G.K. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu. Rev. Physiol. 2012, 74:13-40.
4. Campbell G.R., Campbell J.H. Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp. Mol. Pathol. 1985, 42:139-162.
5. Campbell J.H., Campbell G.R. Smooth muscle phenotypic modulation-a personal experience. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1784-1789.
6. Rovner A.S., Murphy R.A., Owens G.K. Expression of smooth muscle and nonmuscle myosin heavy chains in cultured vascular smooth muscle cells. J. Biol. Chem. 1986, 261:14740-14745.
7. Miano J.M., Cserjesi P., Ligon K.L., Periasamy M., Olson E.N. Smooth muscle myosin heavy chain exclusively marks the smooth muscle lineage during mouse embryogenesis. Circ. Res. 1994, 75:803-812.
8. Winder S.J., Sutherland C., Walsh M.P. Biochemical and functional characterization of smooth muscle calponin. Adv. Exp. Med. Biol. 1991, 304:37-51.
9. Gabbiani G., Schmid E., Winter S., Chaponnier C., de Ckhastonay C., Vandekerckhove J., Weber K., Franke W.W. Vascular smooth muscle cells differ from other smooth muscle cells: predominance of vimentin filaments and a specific alpha-type actin. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:298-302.
10. Miano J.M. Serum response factor: toggling between disparate programs of gene expression. J. Mol. Cell. Cardiol. 2003, 35:577-593.
11. Manabe I., Owens G.K. CArG elements control smooth muscle subtype-specific expression of smooth muscle myosin in vivo. J. Clin. Invest. 2001, 107:823-834.
12. Li L., Miano J.M., Mercer B., Olson E.N. Expression of the SM22alpha promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells. J. Cell Biol. 1996, 132:849-859.
13. Kim S., Ip H.S., Lu M.M., Clendenin C., Parmacek M.S. A serum response factor-dependent transcriptional regulatory program identifies distinct smooth muscle cell sublineages. Mol. Cell. Biol. 1997, 17:2266-2278.
14. Mack C.P., Owens G.K. Regulation of smooth muscle alpha-actin expression in vivo is dependent on CArG elements within the 5' and first intron promoter regions. Circ. Res. 1999, 84:852-861.
15. Du K.L., Ip H.S., Li J., Chen M., Dandre F., Yu W., Lu M.M., Owens G.K., Parmacek M.S. Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol. Cell. Biol. 2003, 23:2425-2437.
16. Mack C.P., Hinson J.S. Regulation of smooth muscle differentiation by the myocardin family of serum response factor co-factors. J. Thromb. Haemost. 2005, 3:1976-1984.
17. Chen J., Kitchen C.M., Streb J.W., Miano J.M. Myocardin: a component of a molecular switch for smooth muscle differentiation. J. Mol. Cell. Cardiol. 2002, 34:1345-1356.
18. Wang Z., Wang D.Z., Hockemeyer D., McAnally J., Nordheim A., Olson E.N. Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 2004, 428:185-189.
19. Yoshida T., Sinha S., Dandre F., Wamhoff B.R., Hoofnagle M.H., Kremer B.E., Wang D.Z., Olson E.N., Owens G.K. Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ. Res. 2003, 92:856-864.
20. Li S., Wang D.Z., Wang Z., Richardson J.A., Olson E.N. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9366-9370.
21. Raines E.W. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004, 15:237-254.
22. Chen Z.Y., Wang X., Zhou Y., Offner G., Tseng C.C. Destabilization of Krüpple-like factor 4 protein in response to serum stimulation involves the ubiquitin-proteasome pathway. Cancer Res. 2005, 65:10394-10400.
23. Quandt K., Frech K., Karas H., Wingender E., Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 1995, 23:4878-4884.
24. Yet S.F., McA'Nulty M.M., Folta S.C., Yen H.W., Yoshizumi M., Hsieh C.M., Layne M.D., Chin M.T., Wang H., Perrella M.A., Jain M.K., Lee M.E. Human EZF, a Krüpple-like zinc finger protein, is expressed in vascular endothelial cells and contains transcriptional activation and repression domains. J. Biol. Chem. 1998, 273:1026-1031.
25. Turner E.C., Kinsella B.T. Regulation of the human prostacyclin receptor gene by the cholesterol-responsive SREBP1. J. Lipid Res. 2012, 53:2390-2404.
26. Li D., Peng Z., Tang H., Wei P., Kong X., Yan D., Huang F., Li Q., Le X., Xie K. KLF4-mediated negative regulation of IFITM3 expression plays a critical role in colon cancer pathogenesis. Clin. Cancer Res. 2011, 17:3558-3568.
27. Gao D., Niu X., Ning N., Hao G. Regulation of angiotensin II-induced Krüpple-like factor 5 expression in vascular smooth muscle cells. Biol. Pharm. Bull. 2006, 29:2004-2008.
28. Bruce S.J., Gardiner B.B., Burke L.J., Gongora M.M., Grimmond S.M., Perkins A.C. Dynamic transcription programs during ES cell differentiation towards mesoderm in serum versus serum-freeBMP4 culture. BMC Genomics 2007, 8:365.
29. McConnell B.B., Yang V.W. Mammalian Krüpple-like factors in health and diseases. Physiol. Rev. 2010, 90:1337-1381.
30. Kaczynski J., Cook T., Urrutia R. Sp1- and Krüpple-like transcription factors. Genome Biol. 2003, 4:206.
31. Pearson R., Fleetwood J., Eaton S., Crossley M., Bao S. Krüpple-like transcription factors: a functional family. Int. J. Biochem. Cell Biol. 2008, 40:1996-2001.
32. Yoshida T., Gan Q., Owens G.K. Krüpple-like factor 4, Elk-1, and histone deacetylases cooperatively suppress smooth muscle cell differentiation markers in response to oxidized phospholipids. Am. J. Physiol. Cell Physiol. 2008, 295:C1175-C1182.
33. Chew Y.C., Adhikary G., Wilson G.M., Reece E.A., Eckert R.L. Protein kinase C (PKC) delta suppresses keratinocyte proliferation by increasing p21(Cip1) level by a KLF4 transcription factor-dependent mechanism. J. Biol. Chem. 2011, 286:28772-28782.
34. Deaton R.A., Gan Q., Owens G.K. Sp1-dependent activation of KLF4 is required for PDGF-BB-induced phenotypic modulation of smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1027-H1037.
35. Liu Y., Sinha S., McDonald O.G., Shang Y., Hoofnagle M.H., Owens G.K. Krüpple-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression. J. Biol. Chem. 2005, 280:9719-9727.
36. Owens G.K. Molecular control of vascular smooth muscle cell differentiation and phenotypic plasticity. Novartis Found. Symp. 2007, 283:174-191. (discussion 191-173, 238-141).
37. Campbell J.H., Popadynec L., Nestel P.J., Campbell G.R. Lipid accumulation in arterial smooth muscle cells. Influence of phenotype. Atherosclerosis 1983, 47:279-295.
38. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
39. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 2002, 90:251-262.
40. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 1994, 94:2493-2503.
41. Kawai-Kowase K., Owens G.K. Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am. J. Physiol. Cell Physiol. 2007, 292:C59-C69.
42. Blank R.S., McQuinn T.C., Yin K.C., Thompson M.M., Takeyasu K., Schwartz R.J., Owens G.K. Elements of the smooth muscle alpha-actin promoter required in cis for transcriptional activation in smooth muscle. Evidence for cell type-specific regulation. J. Biol. Chem. 1992, 267:984-989.
43. Dandre F., Owens G.K. Platelet-derived growth factor-BB and Ets-1 transcription factor negatively regulate transcription of multiple smooth muscle cell differentiation marker genes. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H2042-H2051.
44. Wang D., Chang P.S., Wang Z., Sutherland L., Richardson J.A., Small E., Krieg P.A., Olson E.N. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 2001, 105:851-862.
45. Davis-Dusenbery B.N., Chan M.C., Reno K.E., Weisman A.S., Layne M.D., Lagna G., Hata A. Down-regulation of Krüpple-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J. Biol. Chem. 2011, 286:28097-28110.
46. Creemers E.E., Sutherland L.B., McAnally J., Richardson J.A., Olson E.N. Myocardin is a direct transcriptional target of Mef2, Tead and Foxo proteins during cardiovascular development. Development 2006, 133:4245-4256.
47. Tan W.Q., Wang K., Lv D.Y., Li P.F. Foxo3a inhibits cardiomyocyte hypertrophy through transactivating catalase. J. Biol. Chem. 2008, 283:29730-29739.
48. Yang X., Gong Y., Tang Y., Li H., He Q., Gower L., Liaw L., Friesel R.E. Spry1 and Spry4 differentially regulate human aortic smooth muscle cell phenotype via Akt/FoxO/Myocardin signaling. PLoS One 2013, 8:e58746.
49. Lovren F., Pan Y., Quan A., Singh K.K., Shukla P.C., Gupta N., Steer B.M., Ingram A.J., Gupta M., Al-Omran M., Teoh H., Marsden P.A., Verma S. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012, 126:S81-S90.
50. Liu Y., Sinha S., Owens G. A transforming growth factor-beta control element required for SM alpha-actin expression in vivo also partially mediates GKLF-dependent transcriptional repression. J. Biol. Chem. 2003, 278:48004-48011.
51. Bornfeldt K.E., Raines E.W., Nakano T., Graves L.M., Krebs E.G., Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J. Clin. Invest. 1994, 93:1266-1274.
52. Jackson C.L., Raines E.W., Ross R., Reidy M.A. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler. Thromb. 1993, 13:1218-1226.
53. Blank R.S., Owens G.K. Platelet-derived growth factor regulates actin isoform expression and growth state in cultured rat aortic smooth muscle cells. J. Cell. Physiol. 1990, 142:635-642.
54. Corjay M.H., Thompson M.M., Lynch K.R., Owens G.K. Differential effect of platelet-derived growth factor- versus serum-induced growth on smooth muscle alpha-actin and nonmuscle beta-actin mRNA expression in cultured rat aortic smooth muscle cells. J. Biol. Chem. 1989, 264:10501-10506.
55. Banai S., Wolf Y., Golomb G., Pearle A., Waltenberger J., Fishbein I., Schneider A., Gazit A., Perez L., Huber R., Lazarovichi G., Rabinovich L., Levitzki A., Gertz S.D. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation 1998, 97:1960-1969.
56. Ferns G.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A., Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991, 253:1129-1132.
57. Libby P., Warner S.J., Salomon R.N., Birinyi L.K. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N. Engl. J. Med. 1988, 318:1493-1498.